We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

74 hedge funds and large institutions have $46.7M invested in Navidea Biopharmaceuticals Inc. in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 78 → 74 (-4)

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

22% less capital invested

Capital invested by funds: $60.2M → $46.7M (-$13.4M)

24% less call options, than puts

Call options by funds: $65K | Put options by funds: $85K

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

Holders
74
Holders Change
-4
Holders Change %
-5.13%
% of All Funds
1.97%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
17
Reduced
20
Closed
12
Calls
$65K
Puts
$85K
Net Calls
-$20K
Net Calls Change
+$7.97M

Top Buyers

Rank Fund Capital Flow
1
PM
Platinum Management
New York
+$11.7M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$95.1K
3
SG Americas Securities
SG Americas Securities
New York
+$93.5K
4
Citigroup
Citigroup
New York
+$79K
5
RFC
Russell Frank Company
Washington
+$67.5K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$5.87M
2
Renaissance Technologies
Renaissance Technologies
New York
-$807K
3
Goldman Sachs
Goldman Sachs
New York
-$277K
4
BFA
BlackRock Fund Advisors
California
-$200K
5
UBS Group
UBS Group
Switzerland
-$160K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$122K +$79K +4,107 +177%
Creative Planning
27
Creative Planning
Kansas
$119K – – –
Manulife (Manufacturers Life Insurance)
28
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$93K +$847 +44 +0.9%
SG Americas Securities
29
SG Americas Securities
New York
$92K +$93.5K +4,861 New
SI
30
SII Investments
Wisconsin
$86K +$18.6K +965 +27%
AIG
31
American International Group
New York
$85K – – –
VOYA Investment Management
32
VOYA Investment Management
Georgia
$79K – – –
Wells Fargo
33
Wells Fargo
California
$73K +$7.68K +399 +12%
BA
34
BlackRock Advisors
Delaware
$72K +$9.83K +511 +15%
RFC
35
Russell Frank Company
Washington
$67K +$67.5K +3,510 New
T. Rowe Price Associates
36
T. Rowe Price Associates
Maryland
$66K – – –
GWM
37
Greenwich Wealth Management
Connecticut
$61K – – –
State Board of Administration of Florida Retirement System
38
State Board of Administration of Florida Retirement System
Florida
$57K – – –
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$55K -$5.87M -304,989 -99%
Nomura Holdings
40
Nomura Holdings
Japan
$54K +$54.8K +2,850 New
SW
41
SVB Wealth
Massachusetts
$44K – – –
Tudor Investment Corp
42
Tudor Investment Corp
Connecticut
$44K – – –
Jacobs Levy Equity Management
43
Jacobs Levy Equity Management
New Jersey
$43K +$43.4K +2,255 New
SWP
44
Stratos Wealth Partners
Ohio
$40K – – –
AllianceBernstein
45
AllianceBernstein
Tennessee
$33K -$10.1K -525 -23%
Commonwealth Equity Services
46
Commonwealth Equity Services
Massachusetts
$33K – – –
LFG
47
LifePlan Financial Group
Ohio
$27K – – –
Principal Financial Group
48
Principal Financial Group
Iowa
$24K – – –
Deutsche Bank
49
Deutsche Bank
Germany
$22K -$25.4K -1,322 -51%
Group One Trading
50
Group One Trading
Illinois
$20K +$20.6K +1,068 New
1
2
3 4

NAVB Hedge Fund Activity: Q1 2016 in Review

74 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2016, worth a combined $46.7M — down 22% from $60.2M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of NAVB and 8 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 17 added.

The largest buyer was Platinum Management, adding an estimated $11.7M. The largest seller was Susquehanna International Group, cutting an estimated $5.87M.

  • 74 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2016, down from 78 in Q4 2015.
  • Funds reported $46.7M of Navidea Biopharmaceuticals Inc. stock for Q1 2016, down 22% quarter-over-quarter.
  • 8 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2016 and 12 closed out, a net change of -4 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2016 was Platinum Management, an estimated $11.7M added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2016 was Susquehanna International Group, an estimated $5.87M sold.

Based on aggregated 13F filings for Q1 2016.